Klumper is replacing Eric van der Putten who leaves his role as CEO to become Chief Business Development Officer, responsible for driving new business opportunities and growing SMS Oncology’s client base.
“Our clients will benefit discussing their new cancer studies with Eric who brings to the table 30+ years of experience in running phase I and II cancer trials in close collaboration with the top tier of oncologists,” said new CEO Edwin Klumper. “His experience and operational insights will be of great value to our clients in achieving their objectives.”
The latest faces in drug discovery, CROs, and research charities.
Results from the 50 Most Influential People in Vaccines, Aligent changes CEOs, and more...
On the eve of the historical vote on Scottish independence from the UK tomorrow, we take a...
New execs for ICON and PPD, plus services shake-ups in this week's column.